58 related articles for article (PubMed ID: 20015219)
1. Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2.
Ghezzi S; Pacciarini F; Nozza S; Racca S; Mariani SA; Vicenzi E; Lazzarin A; Veglia F; Tambussi G; Poli G
HIV Med; 2010 May; 11(5):349-52. PubMed ID: 20015219
[TBL] [Abstract][Full Text] [Related]
2. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
[TBL] [Abstract][Full Text] [Related]
3. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
4. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.
Karlsson I; Grivel JC; Chen SS; Karlsson A; Albert J; Fenyö EM; Margolis LB
J Virol; 2005 Sep; 79(17):11151-60. PubMed ID: 16103166
[TBL] [Abstract][Full Text] [Related]
5. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
6. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.
Karlsson I; Antonsson L; Shi Y; Karlsson A; Albert J; Leitner T; Olde B; Owman C; Fenyö EM
AIDS; 2003 Dec; 17(18):2561-9. PubMed ID: 14685050
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
8. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac.
Chen Z; Gettie A; Ho DD; Marx PA
Virology; 1998 Jun; 246(1):113-24. PubMed ID: 9656999
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
[TBL] [Abstract][Full Text] [Related]
10. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
[TBL] [Abstract][Full Text] [Related]
11. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
[TBL] [Abstract][Full Text] [Related]
12. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
13. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
[TBL] [Abstract][Full Text] [Related]
14. [HIV-1 co-receptor usage of patients experienced anti-retroviral therapy].
Qu SL; Yuan L; Huang Y; Xu WS; Yu XL; Liu YL; Xing H; Shao YM; Ma LY
Zhonghua Yu Fang Yi Xue Za Zhi; 2010 Nov; 44(11):985-8. PubMed ID: 21215124
[TBL] [Abstract][Full Text] [Related]
15. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
16. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.
Jansson M; Backström E; Björndal A; Holmberg V; Rossi P; Fenyö EM; Popovic M; Albert J; Wigzell H
J Hum Virol; 1999; 2(6):325-38. PubMed ID: 10774549
[TBL] [Abstract][Full Text] [Related]
17. Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.
Burighel N; Ghezzi S; Nozza S; Del Bianco P; Lazzarin A; Tambussi G; Poli G; De Rossi A
Haematologica; 2006 Feb; 91(2):244-7. PubMed ID: 16461311
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
[TBL] [Abstract][Full Text] [Related]
19. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
Equils O; Garratty E; Wei LS; Plaeger S; Tapia M; Deville J; Krogstad P; Sim MS; Nielsen K; Bryson YJ
J Infect Dis; 2000 Sep; 182(3):751-7. PubMed ID: 10950768
[TBL] [Abstract][Full Text] [Related]
20. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H; Maeda K; Miyakawa T; Shibayama S; Matsuo M; Takaoka Y; Ito M; Koyanagi Y; Mitsuya H
J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
